世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

ジストニア治療薬市場:薬剤タイプ別(抗痙攣薬、その他、ドパミン作動薬、GABA作動薬)、投与経路別(経口剤、注射剤)、流通チャネル別(病院薬局、オンラインプロバイダー、ドラッグストア・小売薬局)、地域別(北米、欧州、APAC、RoW) - 2027年までの予測


Dystonia Drugs Market by Drug Type (Anticonvulsants drugs, Others, Dopaminergic agents and GABAergic agents), Route of Administration (Oral and Injectable), Distribution Channel (Hospital Pharmacies, Online Providers and Drug Stores and Retail Pharmacies) and Geography (North America, Europe, APAC and RoW) - Forecast up to 2027

ジストニアは、ゆっくりとした反復運動や異常な姿勢を引き起こす不随意的な筋収縮を特徴とする運動障害を指す。これらの筋収縮は、異常な筋肉の動きや体の姿勢を引き起こす。ジストニアには様々なタイプがあり、... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
IHR Insights
アイエイチアールインサイト
2023年7月6日 US$4,500
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
180 英語

 

サマリー

ジストニアは、ゆっくりとした反復運動や異常な姿勢を引き起こす不随意的な筋収縮を特徴とする運動障害を指す。これらの筋収縮は、異常な筋肉の動きや体の姿勢を引き起こす。ジストニアには様々なタイプがあり、単一の筋肉に影響を及ぼすもの、複数の筋肉に影響を及ぼすもの、全身の筋肉に影響を及ぼすものなどがある。ジストニア治療薬市場の成長は、発展途上の医療インフラの利用可能性、満たされていない医療ニーズの増加、高度医療施設に対する需要の増加により、未開拓の新興市場における高い可能性によって牽引されると予測される。さらに、ジストニアの有病率の急増と、ジストニア症状を有する他の神経疾患の発生率の急増が、市場の成長を促進しています。このようなジストニアの発生率の増加は、ジストニア治療薬の需要を増大させ、ジストニア治療薬市場シェアの成長をさらに加速させます。しかし、ジストニアの治療にかかる莫大な費用が市場の成長を制限する可能性があります。ジストニア治療薬市場は、2027年までに年平均成長率5.3%で成長すると予測される。
ジストニア治療薬市場:薬剤タイプ別
- 抗けいれん薬
- その他
- ドパミン作用薬
- GABA作動性薬剤
ジストニア治療薬の投与経路別市場
- 経口剤
- 注射剤
ジストニア治療薬の流通経路別市場
- 病院薬局
- オンラインプロバイダー
- ドラッグストアおよび小売薬局
ジストニア治療薬の地域別市場
- 北米
- 欧州
- アジア太平洋
- その他の地域
製品タイプ別に見ると、抗けいれん薬、その他、ドーパミン作動薬、GABA作動薬に分けられる。GABA作動性製剤は市場で最大のシェアを占めている。この成長は、ジストニア、特に頸部ジストニアの治療における利点によるものである。さらに、ジストニアの治療に非常に有効で強力なGABA作動性薬剤が発見され、医療専門家による処方が拡大していることも、予測期間における同分野の成長を後押ししている。
投与経路別に見ると、市場は経口剤と注射剤に二分される。このうち、注射剤が市場で大きなシェアを占めている。これは、非経口投与における技術革新の増加や、ボツリヌス注射薬の研究開発の増加によるものです。薬、特に水溶液の吸収は迅速で均一です。経口や皮下投与に比べ、効果の発現が早い。
流通チャネルは、病院薬局、オンラインプロバイダー、ドラッグストア・小売薬局に分類される。ドラッグストア・小売薬局部門が市場で最大のシェアを占めている。これは、流通網が充実しており、消費者に医薬品を提供するための最も古く簡単なチャネルであるためである。小売薬剤師は医薬品の調剤・配置を行い、消費者に医薬品の適切な使用方法をアドバイスし、相互作用の可能性を知らせる。
地域別分析では、北米地域が市場で大きなシェアを獲得している。ジストニアの罹患率の急増と、米国人口および他の主要国におけるジストニアを引き起こす他の神経疾患の有病率の急増が、北米におけるジストニア治療薬の需要を増大させる主な要因となっている。
連邦政府は、処方薬の需要を増大させるプログラム、新薬の供給に影響を与える政策(基礎研究への投資や臨床試験で実証されなければならない内容に関する規制など)、需要と供給の両方に影響を与える政策(ワクチンの推奨など)を通じて、民間の研究開発投資に影響を与えている。製薬業界における世界的な研究開発の急増は、ジストニア治療薬の有効性とその利用を改善し、世界市場の成長を促進すると考えられます。
本レポートには、市場で事業を展開する主要ベンダー、Teva Pharmaceuticals Industries Ltd., F.Hoffmann-La Roche Ltd., Merz Pharma GmbH & Co.KGaA、Ipsen Pharma Biotech SAS、Hameln Pharma Gmbh(Siegfried Group, LLP)、AbbVie, Inc.、Amneal Pharmaceuticals, Inc.、Wellona Pharma、Pfizer, Inc.、Novartis AGが含まれます。
今後、ジストニア治療薬市場は、推定される時間スパンで重要な目撃することが予想されます。すべての治療法と比較して、薬剤はジストニアのための最良の選択肢であると考えられているからです。ジストニア治療薬は、迅速かつ完全な救済を提供すると考えられています。
- このレポートは、ジストニア治療薬市場を調査し、急成長が予測される地域と主要シェアを占めるサブセグメントを予測しています。
- この調査レポートは、ジストニア治療薬市場の成長を促す要因と制限する要因、落とし穴と機会を提供することを示唆しています。
- 本レポートはまた、市場の主要ベンダーの情報と市場における地位で構成されています。
- 本レポートはまた、ジストニア治療薬市場で起こっている絶え間ない市場開発とイノベーションで構成されています。


ページTOPに戻る


目次

1. Executive Summary
2. Industry Outlook
2.1. Industry Overview
2.2. Industry Trends
3. Market Snapshot
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. Market characteristics
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. Drug Type: Market Size & Analysis
5.1. Overview
5.2. Anticonvulsants drugs
5.3. Others
5.4. Dopaminergic agents
5.5. GABAergic agents
6. Route of Administration: Market Size & Analysis
6.1. Overview
6.2. Oral
6.3. Injectable
7. Distribution Channel: Market Size & Analysis
7.1. Overview
7.2. Hospital Pharmacies
7.3. Online Providers
7.4. Drug Stores and Retail Pharmacies
8. Geography: Market Size & Analysis
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. Competitive Landscape
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. Vendor Profiles
10.1. Teva Pharmaceuticals Industries Ltd.
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. F.Hoffmann-La Roche Ltd.
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. Merz Pharma GmbH & Co. KGaA
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. Ipsen Pharma Biotech SAS
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. Hameln Pharma Gmbh (Siegfried Group, LLP)
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. AbbVie, Inc.
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. Amneal Pharmaceuticals, Inc.
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. Wellona Pharma
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. Pfizer, Inc.
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. Novartis AG
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. Analyst Opinion
12. Annexure
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations

ページTOPに戻る



図表リスト

TABLE 1. GLOBAL DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 2. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR ANTICONVULSANTS DRUGS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR DOPAMINERGIC AGENTS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR GABAERGIC AGENTS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR ORAL, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR INJECTABLE, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR HOSPITAL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 11. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR ONLINE PROVIDERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 12. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR DRUG STORES AND RETAIL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 13. NORTH AMERICA DYSTONIA DRUGS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 14. NORTH AMERICA DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 15. NORTH AMERICA DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 16. NORTH AMERICA DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 17. U.S DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 18. U.S DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 19. U.S DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 20. CANADA DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 21. CANADA DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 22. CANADA DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 23. EUROPE DYSTONIA DRUGS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 24. EUROPE DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 25. EUROPE DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 26. EUROPE DYSTONIA DRUGS MARKET VALUE, DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 27. GERMANY DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 28. GERMANY DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 29. GERMANY DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 30. U.K DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 31. U.K DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 32. U.K DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 33. FRANCE DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 34. FRANCE DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 35. FRANCE DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 36. ITALY DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 37. ITALY DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 38. ITALY DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 39. SPAIN DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 40. SPAIN DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 41. SPAIN DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 42. ROE DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 43. ROE DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 44. ROE DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 45. ASIA PACIFC DYSTONIA DRUGS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 46. ASIA PACIFC DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 47. ASIA PACIFC DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 48. ASIA PACIFC DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 49. CHINA DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 50. CHINA DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 51. CHINA DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 52. INDIA DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 53. INDIA DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 54. INDIA DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 55. JAPAN DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 56. JAPAN DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 57. JAPAN DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 58. REST OF APAC DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 59. REST OF APAC DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 60. REST OF APAC DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 61. REST OF WORLD DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 62. REST OF WORLD DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 63. REST OF WORLD DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 64. TEVA PHARMACEUTICALS INDUSTRIES LTD.: FINANCIALS
TABLE 65. TEVA PHARMACEUTICALS INDUSTRIES LTD.: PRODUCTS & SERVICES
TABLE 66. TEVA PHARMACEUTICALS INDUSTRIES LTD.: RECENT DEVELOPMENTS
TABLE 67. F.HOFFMANN-LA ROCHE LTD.: FINANCIALS
TABLE 68. F.HOFFMANN-LA ROCHE LTD.: PRODUCTS & SERVICES
TABLE 69. F.HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS
TABLE 70. MERZ PHARMA GMBH & CO. KGAA: FINANCIALS
TABLE 71. MERZ PHARMA GMBH & CO. KGAA: PRODUCTS & SERVICES
TABLE 72. MERZ PHARMA GMBH & CO. KGAA: RECENT DEVELOPMENTS
TABLE 73. IPSEN PHARMA BIOTECH SAS: FINANCIALS
TABLE 74. IPSEN PHARMA BIOTECH SAS: PRODUCTS & SERVICES
TABLE 75. IPSEN PHARMA BIOTECH SAS: RECENT DEVELOPMENTS
TABLE 76. HAMELN PHARMA GMBH (SIEGFRIED GROUP, LLP): FINANCIALS
TABLE 77. HAMELN PHARMA GMBH (SIEGFRIED GROUP, LLP): PRODUCTS & SERVICES
TABLE 78. HAMELN PHARMA GMBH (SIEGFRIED GROUP, LLP): RECENT DEVELOPMENTS
TABLE 79. ABBVIE, INC.: FINANCIALS
TABLE 80. ABBVIE, INC.: PRODUCTS & SERVICES
TABLE 81. ABBVIE, INC.: RECENT DEVELOPMENTS
TABLE 82. AMNEAL PHARMACEUTICALS, INC.: FINANCIALS
TABLE 83. AMNEAL PHARMACEUTICALS, INC.: PRODUCTS & SERVICES
TABLE 84. AMNEAL PHARMACEUTICALS, INC.: RECENT DEVELOPMENTS
TABLE 85. WELLONA PHARMA: FINANCIALS
TABLE 86. WELLONA PHARMA: PRODUCTS & SERVICES
TABLE 87. WELLONA PHARMA: RECENT DEVELOPMENTS
TABLE 88. PFIZER, INC.: FINANCIALS
TABLE 89. PFIZER, INC.: PRODUCTS & SERVICES
TABLE 90. PFIZER, INC.: RECENT DEVELOPMENTS
TABLE 91. NOVARTIS AG: FINANCIALS
TABLE 92. NOVARTIS AG: PRODUCTS & SERVICES
TABLE 93. NOVARTIS AG: RECENT DEVELOPMENTS

 

ページTOPに戻る


 

Summary

Dystonia can be referred to a movement disorder featured by involuntary muscle contractions which cause slow repetitive movements or abnormal postures. These muscle contractions result in unusual muscle movements and body postures. There are various types of dystonia affecting a single muscle, or a group of muscles or may affect muscles all over the body. The rise of the dystonia drugs market is projected to be driven by high potential in untapped, rising markets, owing to availability of developing healthcare infrastructure, rise in unmet healthcare needs, and rise in demand for advanced healthcare facilities. Additionally, surge in prevalence of dystonia and also surge in incidence of other neurological disorders having dystonia symptoms is propelling the growth of the market. This increase in incidence of dystonia, augments the demand for dystonia treatment medications which further accelerates the growth of the dystonia drugs market share. However, the huge costs incurred in the treatment of dystonia may limit the market growth. The Dystonia Drugs Market is anticipated to grow at a rate of 5.3% CAGR by 2027.
Dystonia Drugs Market by Drug Type
• Anticonvulsants drugs
• Others
• Dopaminergic agents
• GABAergic agents
Dystonia Drugs Market by Route of Administration
• Oral
• Injectable
Dystonia Drugs Market by Distribution Channel
• Hospital Pharmacies
• Online Providers
• Drug Stores and Retail Pharmacies
Dystonia Drugs Market by Geography
• North America
• Europe
• Asia Pacific
• Rest of the World
The market based product type is divided into Anticonvulsants drugs, Others, Dopaminergic agents and GABAergic agents. GABAergic agents segment has the largest share in the market. The growth is ascribed to its advantages in treating dystonia, especially cervical dystonia. Moreover, the discovery of highly effective and potent GABAergic agent pharmaceuticals for treating dystonia, along with its more extensive prescription by healthcare experts, is boosting the segment's growth in the forecasted period.
As per the market by route of administration, the market is bifurcated into Oral and Injectable. Among them the injectable segment has the substantial share in the market. This is due to the increase in innovations in parenteral dosing and increased research and development for botulinum injections. Absorption of the medication, particularly aqueous solutions, is rapid and uniform. There is a swift commencement of effect compared to the oral and subcutaneous methods.
The distribution channel segment is classified into Hospital Pharmacies, Online Providers and Drug Stores and Retail Pharmacies. The drug stores & retail pharmacies segment is accounted for the maximum share in the market. This is because of its substantial chain of distribution networks and it being the oldest and most easy channel for providing drugs to consumers. Retail pharmacists prepare and dispense drugs, advise consumers on the proper use of medications, and inform them of possible drug interactions.
In market by geographical analysis, the North America region has acquired a substantial share in the market. The surge in incidences of dystonia coupled with surge in prevalence of other neurological conditions causing dystonia in U.S. population and other major nations is the key factor for augmenting demand for dystonia drugs in North America.
The federal government influences private investment on research and development through programs which augment the demand for prescription drugs, through policies (such as investment for basic research and regulations on what must be demonstrated in clinical trials) which affect the supply of new medicines, and through policies (such as vaccine recommendations) which affect both supply and demand. The surging R&D in the pharmaceutical industry worldwide is likely to improve the effectiveness of dystonia drugs and their utilization, thereby fueling the global market growth.
This report includes the key vendors operating in the market- Teva Pharmaceuticals Industries Ltd., F.Hoffmann-La Roche Ltd., Merz Pharma GmbH & Co. KGaA, Ipsen Pharma Biotech SAS, Hameln Pharma Gmbh (Siegfried Group, LLP), AbbVie, Inc., Amneal Pharmaceuticals, Inc., Wellona Pharma, Pfizer, Inc. and Novartis AG.
Henceforth, the dystonia drugs market is anticipated to witnessing a significant in the estimated time span. Since, compared to all treatments the drugs are considered to be the best option for the dystonia. The drugs are deemed to provide the quick and complete relief for the ailment.
• This report of Dystonia Drugs market depicts the geographical regions and sub segment which is projected to have the rapid growth and having the major share.
• This study implies the factors which are compelling and restricting the market growth and the providing pitfalls and opportunities for the Dystonia Drugs market.
• This report also consists of information of the market’s leading vendors and their position in the market.
• This report also consists of constant market developments and innovations taking place in the Dystonia Drugs market.



ページTOPに戻る


Table of Contents

1. Executive Summary
2. Industry Outlook
2.1. Industry Overview
2.2. Industry Trends
3. Market Snapshot
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. Market characteristics
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. Drug Type: Market Size & Analysis
5.1. Overview
5.2. Anticonvulsants drugs
5.3. Others
5.4. Dopaminergic agents
5.5. GABAergic agents
6. Route of Administration: Market Size & Analysis
6.1. Overview
6.2. Oral
6.3. Injectable
7. Distribution Channel: Market Size & Analysis
7.1. Overview
7.2. Hospital Pharmacies
7.3. Online Providers
7.4. Drug Stores and Retail Pharmacies
8. Geography: Market Size & Analysis
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. Competitive Landscape
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. Vendor Profiles
10.1. Teva Pharmaceuticals Industries Ltd.
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. F.Hoffmann-La Roche Ltd.
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. Merz Pharma GmbH & Co. KGaA
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. Ipsen Pharma Biotech SAS
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. Hameln Pharma Gmbh (Siegfried Group, LLP)
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. AbbVie, Inc.
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. Amneal Pharmaceuticals, Inc.
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. Wellona Pharma
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. Pfizer, Inc.
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. Novartis AG
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. Analyst Opinion
12. Annexure
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations

ページTOPに戻る



List of Tables/Graphs

TABLE 1. GLOBAL DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 2. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR ANTICONVULSANTS DRUGS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR DOPAMINERGIC AGENTS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR GABAERGIC AGENTS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR ORAL, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR INJECTABLE, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR HOSPITAL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 11. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR ONLINE PROVIDERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 12. GLOBAL DYSTONIA DRUGS MARKET VALUE FOR DRUG STORES AND RETAIL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 13. NORTH AMERICA DYSTONIA DRUGS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 14. NORTH AMERICA DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 15. NORTH AMERICA DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 16. NORTH AMERICA DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 17. U.S DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 18. U.S DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 19. U.S DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 20. CANADA DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 21. CANADA DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 22. CANADA DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 23. EUROPE DYSTONIA DRUGS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 24. EUROPE DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 25. EUROPE DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 26. EUROPE DYSTONIA DRUGS MARKET VALUE, DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 27. GERMANY DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 28. GERMANY DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 29. GERMANY DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 30. U.K DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 31. U.K DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 32. U.K DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 33. FRANCE DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 34. FRANCE DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 35. FRANCE DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 36. ITALY DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 37. ITALY DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 38. ITALY DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 39. SPAIN DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 40. SPAIN DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 41. SPAIN DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 42. ROE DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 43. ROE DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 44. ROE DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 45. ASIA PACIFC DYSTONIA DRUGS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 46. ASIA PACIFC DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 47. ASIA PACIFC DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 48. ASIA PACIFC DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 49. CHINA DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 50. CHINA DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 51. CHINA DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 52. INDIA DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 53. INDIA DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 54. INDIA DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 55. JAPAN DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 56. JAPAN DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 57. JAPAN DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 58. REST OF APAC DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 59. REST OF APAC DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 60. REST OF APAC DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 61. REST OF WORLD DYSTONIA DRUGS MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
TABLE 62. REST OF WORLD DYSTONIA DRUGS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)
TABLE 63. REST OF WORLD DYSTONIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
TABLE 64. TEVA PHARMACEUTICALS INDUSTRIES LTD.: FINANCIALS
TABLE 65. TEVA PHARMACEUTICALS INDUSTRIES LTD.: PRODUCTS & SERVICES
TABLE 66. TEVA PHARMACEUTICALS INDUSTRIES LTD.: RECENT DEVELOPMENTS
TABLE 67. F.HOFFMANN-LA ROCHE LTD.: FINANCIALS
TABLE 68. F.HOFFMANN-LA ROCHE LTD.: PRODUCTS & SERVICES
TABLE 69. F.HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS
TABLE 70. MERZ PHARMA GMBH & CO. KGAA: FINANCIALS
TABLE 71. MERZ PHARMA GMBH & CO. KGAA: PRODUCTS & SERVICES
TABLE 72. MERZ PHARMA GMBH & CO. KGAA: RECENT DEVELOPMENTS
TABLE 73. IPSEN PHARMA BIOTECH SAS: FINANCIALS
TABLE 74. IPSEN PHARMA BIOTECH SAS: PRODUCTS & SERVICES
TABLE 75. IPSEN PHARMA BIOTECH SAS: RECENT DEVELOPMENTS
TABLE 76. HAMELN PHARMA GMBH (SIEGFRIED GROUP, LLP): FINANCIALS
TABLE 77. HAMELN PHARMA GMBH (SIEGFRIED GROUP, LLP): PRODUCTS & SERVICES
TABLE 78. HAMELN PHARMA GMBH (SIEGFRIED GROUP, LLP): RECENT DEVELOPMENTS
TABLE 79. ABBVIE, INC.: FINANCIALS
TABLE 80. ABBVIE, INC.: PRODUCTS & SERVICES
TABLE 81. ABBVIE, INC.: RECENT DEVELOPMENTS
TABLE 82. AMNEAL PHARMACEUTICALS, INC.: FINANCIALS
TABLE 83. AMNEAL PHARMACEUTICALS, INC.: PRODUCTS & SERVICES
TABLE 84. AMNEAL PHARMACEUTICALS, INC.: RECENT DEVELOPMENTS
TABLE 85. WELLONA PHARMA: FINANCIALS
TABLE 86. WELLONA PHARMA: PRODUCTS & SERVICES
TABLE 87. WELLONA PHARMA: RECENT DEVELOPMENTS
TABLE 88. PFIZER, INC.: FINANCIALS
TABLE 89. PFIZER, INC.: PRODUCTS & SERVICES
TABLE 90. PFIZER, INC.: RECENT DEVELOPMENTS
TABLE 91. NOVARTIS AG: FINANCIALS
TABLE 92. NOVARTIS AG: PRODUCTS & SERVICES
TABLE 93. NOVARTIS AG: RECENT DEVELOPMENTS

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

IHR Insights社の医療分野での最新刊レポート

本レポートと同じKEY WORD(agents)の最新刊レポート


よくあるご質問


IHR Insights社はどのような調査会社ですか?


IHR InsightsはICT、化学品、ヘルスケア、半導体など、世界の幅広い分野を対象に調査し、専門的な知識を基に市場調査報告書を出版しています。 主な調査分野 ◇ICT ◇化学品、材料、... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/15 10:26

157.84 円

166.62 円

202.61 円

ページTOPに戻る